Sahil Khanna, MBBS: Emerging Therapies for C Difficile

Video

Recent studies have shown the majority of potential FMT donors are ultimately rejected.

Much of the focus in recent years in new therapies for Clostridioides difficile infections (CDI) has centered on fecal microbiota transplantation (FMT).

Fecal microbiota transplantation is a procedure where healthy donor stool is infused to rectify the recipient’s intestinal microbial community by introducing micro-organisms associated with a health state to normalize microbiota composition and function.

This treatment has shown promise, particularly in treating recurrent CDI. However, it can be a struggle finding suitable donors.

Donors are often rejected for a number of reasons, ranging from high body mass index (BMI) to underlying chronic illnesses to recent use of antibiotics.

While it is challenging to find suitable donors, a small sampling of donors can make a big difference.

In an interview with HCPLive®, Sahil Khanna, MBBS, Professor of Medicine, Mayo Clinic, explained why FMT has so much promise and why it is not too concerning that only a small percentage of donor candidates materialize.

Khanna said unlike blood donors who have a limit to how much blood they can donate, a small amount of stool donors are able to produce a large amount of donations.

On October 14, Khanna chaired an HCPLive State of Science event called Institutional Perspectives in Infectious Diseases: Management of C. Difficile.

Recent Videos
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive
A Promising Pipeline for COPD
© 2024 MJH Life Sciences

All rights reserved.